Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia.
about
Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumoniaBench-to-bedside review: understanding genetic predisposition to sepsisCauses and consequences of coagulation activation in sepsis: an evolutionary medicine perspectiveThe emergence of human-evolutionary medical genomicsAcute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency.The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis.Survival advantage of heterozygous factor V Leiden carriers in murine sepsis.Ethical considerations in the collection of genetic data from critically ill patients: what do published studies reveal about potential directions for empirical ethics research?Inflammation-associated activation of coagulation and immune regulation by the protein C pathway.Activated protein C action in inflammationInfection-stimulated fibrin deposition controls hemorrhage and limits hepatic bacterial growth during listeriosisInfluence of Factor V Leiden on susceptibility to and outcome from critical illness: a genetic association study.Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory studyThe physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis.Exploration of the host haemostatic system by group A streptococcus: implications in searching for novel antimicrobial therapiesRegulation of macrophage procoagulant responses by the tissue factor cytoplasmic domain in endotoxemia.Identifying novel genetic determinants of hemostatic balance.Exacerbated venous thromboembolism in mice carrying a protein S K196E mutationInherited defects of coagulation Factor V: the thrombotic side.Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in miceFactor V Leiden as a common genetic risk factor for venous thromboembolism.A guide to murine coagulation factor structure, function, assays, and genetic alterations.Genetic association studies in VLBW infants exemplifying susceptibility to sepsis--recent findings and implications for future research.The emerging role of coagulation proteases in kidney disease.The Yin-Yang of thrombin and activated protein C.Reduced thrombin generation increases host susceptibility to group A streptococcal infectionWhere genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.Protective mechanisms of activated protein C in severe inflammatory disorders.Lack of association between factor V Leiden and sepsis: a meta-analysis.Lower plasma creatinine and urine albumin in individuals at increased risk of type 2 diabetes with factor v leiden mutation.Role of lipopolysaccharide and cecal ligation and puncture on blood coagulation and inflammation in sensitive and resistant mice models.Protein C concentrate controls leukocyte recruitment during inflammation and improves survival during endotoxemia after efficient in vivo activationIndividual clotting factor contributions to mortality following trauma.Pneumococcal meningitis and endocarditis in an infant: possible improved survival with factor V Leiden mutation.A case report of a new pulmonary embolism occurring in a patient receiving continuous infusion of recombinant activated protein C.Should all septic patients be given systemic anticoagulation? No.NADPH oxidase activity selectively modulates vascular endothelial growth factor signaling pathways.Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis.An age-related decrease in factor V Leiden frequency among Polish subjects.Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.
P2860
Q21194921-6770F05B-9990-4103-924A-A2F6C67DD5BFQ24791408-60BDC84B-57D8-4C28-B825-1FE7E25B51B7Q26995417-957490C6-641C-4CFC-825B-AB76A0316F8EQ28729955-3B23B887-FCD3-4CB1-9039-2C4249B908AEQ33373012-B5A6CFB2-D436-4D7D-A3B3-A175244E8C95Q33377815-868FDE71-B81F-4F06-9989-9CB5C1AD732DQ33420513-638FE7D9-C291-43D3-AFE0-F3F9A5F2AE80Q33517601-A9577EF2-A37B-44D2-AC7F-760010D68728Q33766589-2AAF6FC2-9444-4480-B0C8-4E0CCA999044Q33846825-CD054731-7A23-4BE1-88F8-FEB552DECFFBQ33883280-41F0898C-8738-4165-83B2-CC7725E7FCB4Q33919017-F9534AF4-7CF8-4A71-8FE5-40536BE58751Q34153324-CB2DA36A-4A56-4806-8B00-4ED35C34AF3BQ34378782-59BD3EFB-CF3C-4703-84A4-7326AB1DE5F9Q35149917-FD023BFF-0DA4-4908-A6CD-F5EEC7458321Q35839848-4CDB49B1-B1B0-4499-986C-E9B69C367E03Q36230809-E120353B-BA00-4191-B1DD-BEF637212EEFQ36253998-592AFAF6-D113-476D-824D-F6418621B033Q36295650-2FE85E12-0041-4CD4-BDAC-24F3D03FDC34Q36301525-0B600DF2-FF69-4C9B-8766-60E5741142F0Q36437086-0AD96406-BA60-4092-AF15-13F26D8D7825Q36777940-D3423DC7-26F0-4B36-B85C-F54E567B71B3Q36789328-2CA0D8EC-9915-48C4-B08A-D3B404AFD714Q37066587-CEC0BABA-426B-45EC-875B-5122E4ED7B4FQ37084859-6BD9C2F1-6566-4D80-B6E5-641BA0B7AC93Q37086949-71C51918-4AF8-4B99-B318-912B5F47D1C7Q37187461-59B28FD7-9A7C-4937-B07F-7D0314C3289EQ37494702-4ABF4B98-A3EF-48D7-BA9A-7F5C9CD2AA28Q38117275-A3B5ADE0-977A-49C1-84FE-0B6B74292A00Q38367976-892A4B8F-EE5F-42A7-8262-16003F84D27DQ38585956-DFA8ABB5-D07A-43FA-A194-42358779F709Q38865246-98CF9FBF-7AD3-4ED6-B8D6-B6027635672FQ39139392-F4077D8B-F95F-4CD2-A0A9-73236CDCCBC1Q40096448-324684C8-557F-4E2D-8D96-43056730B0C1Q43051654-A41D67D6-ADD7-4938-BBFE-C1A9CE18811AQ44196218-21CFF3E1-D5DD-4E3E-8D93-6360A113408CQ46972328-50BFF7ED-F17C-4D8D-98BC-68868C42E1D5Q47343207-32C05F8C-C396-499C-B6CA-34585D527F3FQ51546713-DAEE28B0-462E-4612-838A-78F19D5DEE23Q51984024-6DC6BABA-9B40-48D0-BB26-295B4A1B5D47
P2860
Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Survival advantage associated ...... psis and in mouse endotoxemia.
@en
Survival advantage associated ...... psis and in mouse endotoxemia.
@nl
type
label
Survival advantage associated ...... psis and in mouse endotoxemia.
@en
Survival advantage associated ...... psis and in mouse endotoxemia.
@nl
prefLabel
Survival advantage associated ...... psis and in mouse endotoxemia.
@en
Survival advantage associated ...... psis and in mouse endotoxemia.
@nl
P2093
P1433
P1476
Survival advantage associated ...... epsis and in mouse endotoxemia
@en
P2093
Berend H Isermann
Bruce R Basson
David E Joyce
Hartmut Weiler
Jean-Francois Dhainaut
John T Brandt
Rashmi Sood
S Betty Yan
P304
P356
10.1182/BLOOD-2003-06-1789
P407
P577
2003-07-17T00:00:00Z